Abstract
Aim: Increasing the endogenous apolipoprotein A-I (ApoA-I) expression has been proposed as a potential therapeutic target for reducing atherosclerotic disease. The aim of this study was to determine whether the novel molecule 4010B-30 identified by high-throughput screening increased the ApoA-I levels in vitro and in vivo, and to evaluate the effect of 4010B-30 on atherogenesis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
